Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Canada-based Kardium has revealed positive one-year efficacy results on its pulsed field ablation (PFA) device, the Globe PF ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

Rising chronic disease burden and increased health awareness are driving significant growth in the global OTC drugs, medical devices and dia ...